Did anyone  else receive an e-mail like this?
Roberta
From time to  time, neurologists, caregivers, and MSA or Parkinson’s disease 
sufferers, their  friends and families, provide us with the addresses of those 
they believe may be  interested in receiving our research updates and 
newsletters on Neuronal  Regeneration. (Also called Neurogenesis). 
They have noticed that our research project  presents innovative approaches 
to treat a number of neurodegenerative disorders.  They have also observed a 
direct improvement in MSA and PD patients who are  following our Neurogenic 
Intervention Programme. They would like to share  research results, in order to 
substantiate the evidence and rationale behind the  use of neurogenic 
intervention programmes. Further research in neuroscience,  clinical data and medical 
reports are required.  
Please let us know if you are interested in this  subject and if you would 
like to receive or contribute with information about  this specific type of 
research.  
We apologise if the above subject is not one of  your particular concern. If 
this is the case, please let us know in order that  we can immediately erase 
your details from our mailing list. 
On the other hand, if you are interested in this  subject, we are pleased to 
inform you about our web site address:
_www.br13.com_ (http://www.br13.com/)   
where you can find general information about this research. 
For more specific research information, with  references relating to 
neurogenesis and also to the aetiology, nutritional and  environmental factors 
concerning MSA and PD, please visit our web site:
_www.shydrager.com_ (http://www.shydrager.com/) 

Every year, we produce a video documentary and  printed enclosures, showing 
the experiences and responses of Parkinson’s disease  and MSA sufferers who 
have followed our neurogenic dietary intervention  programme for some time. 
These documentaries are sent, free of charge, to  doctors, caregivers, 
clinics and also to patients who are really interested in  viewing the practical 
results of this type of research. Please let us know if  you would like to 
receive this material that is available on DVD or VHS, and  where it should be sent. 
 
Since the year 2002, when we first published the  six basic stages on which 
our Neurogenic Dietary Intervention Programme is  based, we have received 
encouraging feedback from doctors and scientists  world-wide. 
For example, in relation to Stage 1 of  the Neurogenic Diet, we received 
various medical reports indicating  that they obtained substantial improvements 
when a re-adjustment of  PD medication was combined with the use of an 
appropriate nutritional  intervention.  
A number of patients who personally researched  Stage 4 of the Neurogenic 
Diet, came across with findings that  led them to the discovery of what was the 
main causative factor of their own  disease. Then, by strictly avoiding further 
contact with this specific causative  agent, they found that their symptoms, 
that had affected them for years,  started now gradually to disappear.  
Also, a large number of patients benefited when  following Stage 6 of The 
Neurogenic Diet. This relates to the  importance of an appropriate exercise 
programme to allow the enhancement of  neuronal regeneration. A number of physical 
therapists developed special  exercise programmes, aiming to enhance 
neurogenic activity in Parkinson’s  disease and in MSA. Soon after, they were able to 
report that, thanks to this  exercise programme, patients were able to reduce 
their need for their medication  by more than 30%.  
in the year 2002, neuroscientists from our team  suggested, that neurogenesis 
can also occur in the dopaminergic system in the  human brain . They observed 
that Parkinson’s Disease and MSA patients, who  followed the neurogenic 
programme, could gradually delay the use of their first  dose of PD medication. 
Some patients were surprised to see that, instead of  needing to start the first 
dose at 7 am, they were able to function normally,  without any medication 
until 10 am. Later on, they realised they could delay it  until 1 pm. Some 
patients were even able to postpone it until late in the  afternoon. 
This was a very clear indication that these  patients had been able to 
restore their own neuronal capabilities to produce  brain neurotransmitters like 
dopamine, without the need of a direct external  source, precursor or dopamine 
agonist.  
Now, in 2004, it has finally been confirmed in a  number of medical and 
scientific research publications, that neurogenesis can  also take place in 
dopaminergic neurons in the substantia nigra in the adult  mammalian brain. These 
areas are the main neuronal systems affected in  Parkinson’s Disease and MSA-P. 
The main objective of our research newsletter is  the dissemination of 
scientific information in relation to neurogenesis. We try  to present this precious 
scientific knowledge, in the clearest way, in order  that a better 
understanding about it, be utilised to improve the quality of life  of Parkinson’s 
Disease and MSA sufferers.  
As an example of one of our previous newsletters  and documentaries, we are 
pleased to enclose below, part of the script of the:  "Documentary on 
Neurogenesis, Year 2003" 
Thank you for your time
Nutritional Medicine Research. 
_www.br13.com_ (http://www.br13.com/) 
_www.shydrager.com_ (http://www.shydrager.com/) 
e-mail: [log in to unmask] 
24 Hour Telephone Help Line and  Information:
In the USA: 520 750  6466
All Other countries: 00-44 7930 915  588  
TEXT FROM VIDEO SCRIPT 
for the Documentary  on 
NEUROGENESIS RESEARCH 
TITLE: 
ORIGINAL HOME-VIDEO CLIPS SHOWING THE  GENUINE PERSONAL EXPERIENCES OF 
PARKINSON’S DISEASE AND MSA  SUFFERERS. 
To assess the degrees of neuronal activity which  can be induced through a 
specific type of intervention, the following  suggestions are indicated for 
Parkinson’s disease and MSA patients:  
1. –The assessment must be done in the morning.  Patients must be free of 
Parkinson’s disease medication and of any medicinal  extract for at least 18 to 
24 hours.  
2. - To determine the degree of advancement of  the disease, find out which 
movements or activities are the most difficult to  perform, before taking the 
early morning extract or the prescribed PD  drugs. 
3. - The ability to perform each task needs to  be evaluated. This 
examination measures, for example, the ability to stand up  from a chair, getting out of 
bed, walking, opening doors, dressing, writing,  taking a bath, etc.  
4. - DNA repair and neuronal regeneration are  slow processes therefore, to 
be able to observe any external changes, the  evaluation tests are usually 
performed at 3 monthly intervals. 
5. - The ability to improve performance in any  of the above activities will 
indicate to us the degree in which the neurogenic  intervention has succeeded. 
 
6. - Most neurological examinations and  disability scales are designed to 
test the ability of a drug to improve mobility  for a limited number of hours, 
following the taking of a specific drug. Here,  instead, we test the ability of 
a treatment to regenerate Neurons. Therefore,  tests need to be taken at a 
time when no drugs or extracts had been used,  whatsoever, for at least 18 
hours. 
7. – An improvement in the performance of any of  the above activities will 
indicate to us that enrichment in brain transmitter  biosynthesis has occurred 
during sleeping hours. This endogenous enhancement of  neurotransmitter 
biosynthesis can only occur as a result of an increase in the  number of active 
brain dopaminergic neurons. 
The first patient shown on our video  documentary is an 89 year old lady, 
diagnosed with Parkinson’s disease 4 years  ago. 
A medical history, and report, with further  details, is available for 
doctors interested in receiving additional information  on this woman.  
In 1999 she was diagnosed with Parkinson’s  disease and prescribed the drug 
Sinemet 25/100. She tried it for a short time,  soon after; this drug had to be 
discontinued due a bad reaction to it and to  undesirable side effects.  
In April 1999, she started our neurogenic  dietary intervention programme, 
which resolved efficiently her gait disturbance  and did not cause her any side 
effects at all. 
After one year of using the neurogenic diet, she  was able to walk 
independently without the aid of a cane. At the time of  diagnosis, she suffered from a 
moderate bradykinesia. One year later, there was  no apparent sign of a 
bradykinetic problem at all.  
During the second year on the neurogenic diet,  she became totally 
independent in the morning. She was able to prepare  breakfast, dress herself and go out 
for a walk without any  assistance. 
After four years on the neurogenic diet, the  disease did not show any 
progression. Instead, there was an apparent  disappearance of many of the initial 
symptoms that lead to the diagnosis of  Parkinson’s disease in 1999.  
In December 2002, at her fourth year on the  neurogenic programme, the woman’
s daughter filmed a tape for us and her doctor  to show that her mother was 
now able to perform exercises which were impossible  to do a year earlier.  
This exercise consists of lying on the floor by  herself and lifting herself 
up from the floor, without assistance. This  demonstration was filmed at 10 
am. The last time she had taken her extract was  the previous day at 6 am, that 
is, 28 hours earlier.  
The exercise that this lady managed to perform  and showed to us is not only 
a difficult exercise to perform by any Parkinson’s  disease patient, but also 
by anyone at the age of 89.  
The exercise that she had done is a difficult  exercise for anyone at the age 
of 89, but particularly for anybody suffering for  Parkinson disease.  
The second patient, presented in this  video, had been suffering from 
Parkinson’s disease for 20  years. 
She is now 78 years old. She is 11 years younger  than the previous patient 
shown in this video. She took Sinemet 25/100, four to  six times a day, during 
the first 15 years she had the disease. During the  period she was taking 
Sinemet, she had sensitive reactions against it, which  made her suffer from a 
number of side effects, over many years. 
She started on the neurogenic diet in 1997, that  is, almost 5 years ago. 
When she started our treatment, she had been unable to  walk for the previous two 
years and had to make use of a wheelchair during the  day. 
With the introduction of the neurogenic diet,  Sinemet was discontinued and 
replaced by our extracts. This approach allowed her  to obtain improvements in 
her mobility and the side effects; she had been  suffering, gradually 
disappeared.  
With the help of the extracts, she was able to  perform essential movements 
without having any form of dyskinesia, freezing  episodes and "off periods". 
However, our treatment could not enhance a proper  neurogenic activity, mainly 
because, being almost all day in a wheelchair, she  had not been able to 
perform any form of exercise or any major muscular  activity; these are essential 
factors needed to activate the processes of  neurogenesis. 
It is important to note that what occurred with  this patient, is the 
opposite of what happened to the 89 year old patient shown  previously who has been 
able to take one hour walks every day. In relation to  this, she made the 
following comment in her home-made video: "If you don’t walk  at all, then you can’
t walk." This personal observation represents her feelings  after realising 
that the more she can walk and exercise, the better her  mobility. Whenever she 
stops walking, she realises that it becomes harder to  start again.  
The experiences of these two patients, confirmed  to us, that exercise and 
physical activity are the two main factors required for  neurogenic processes to 
take place.  
The use of our dietary intervention and extracts  can only enhance the 
process of neurogenesis when the patient is able to perform  a certain amount of 
exercise and physical activity. 
A number of areas of the brain are  affected by MSA. 
This has led to different varieties of MSA  receiving different names, 
depending on which area of the brain has predominant  involvement.  
When a patient initially has rigidity  (stiffness) and slowness in initiating 
movements (bradykinesia) which is out of  proportion to tremour, this MSA 
form has been called striatonigral degeneration,  involving communication between 
nerve cells in the striatum and midbrain. This  is the form of MSA which has 
been diagnosed to the third patient shown in the  video. It is also called 
MSA-P, because it resembles the symptoms of Parkinson’s  disease. 
This patient was diagnosed two years  ago, as having Parkinson’s disease. 
Soon after, her neurologist realised that  she had developed MSA-P. 
This is a Multiple System Atrophy of the  Striatonigral Degeneration Type. 
The patient was experiencing serious  difficulties in breathing, walking, had 
a very poor balance, dryness of mouth,  difficulties in swallowing, 
intermittent sleep, constipation, and several other  symptoms that were making her life 
almost unbearable.  
We asked her family to record a video tape for  us, to allow us to have a 
better understanding of her condition and  problems. 
On the 15th of December 2002, she started on the  first stage of our 
neurogenic diet, which concentrates mainly on the replacement  of any drugs that might 
be causing adverse reactions. 
A few weeks later, as soon as the drugs Sinemet  and Amantadine were reduced 
by 50%, most of the severe symptoms she was  experiencing had decreased 
significantly. 
The family continued to video tape her over the  New Year holidays and, with 
great surprise, they realised that their mother was  showing quick and very 
dramatic improvements. 
This important visual testimony helps to  demonstrate that, in some 
instances, the symptoms thought to be of a Parkinson’s  disease condition progressing 
into an MSA condition, might not be the real  scenario. 
Each and every food contains a tiny  amount of medicinal substances which 
help to heal most human diseases.  
As it is written in  Genesis 1.29. 
"I give  you every seed-bearing plant on the face of the whole earth and 
every tree that  has fruit with seed in it. They will be yours for  food."
Based on this  principle we have build up a number of research projects to 
extract medicinal  substances from food.
One of this is the medicinal extract RG-40.  
RG-40 is an organic vegetable extract, rich in  amino acids and plant kingdom 
biological factors, required for the synthesis of  neuronal dopamine 
receptors. RG-40 natural components are organic substances  which are easily allowed 
to penetrate the blood brain barrier and can access the  Basal Ganglia, where 
they interact with the DNA of dopaminergic  neurons. 
RG-40 biological factors are transported inside  the dopaminergic neurons 
reaching the nucleus, where they interact with DNA. DNA  in the cell nucleus is 
the command centre where orders to carry out the  synthesis of receptor 
proteins are executed. 
Molecular Neurobiology of Dopamine Receptor  Synthesis Induced by RG-40. The 
process begins in the cell nucleus, where RG-40  activates specific genes, 
which induce DNA to be transcribed into messenger  RNA. 
Messenger RNA then travels to the endoplasmic  reticulum where ribosomes 
cause the messenger RNA to be translated into  partially formed dopamine receptor 
proteins. 
The next step is for partially formed dopamine  receptor proteins to be 
transformed into complete dopamine receptor molecules in  the Golgi Apparatus. 
Completely formed dopamine receptor molecules  are proteins and these are 
transported to the cell membrane where they interact  with the neurotransmitter 
dopamine.  
As a result of the interaction between the  neurotransmitter dopamine and 
dopamine receptor molecules, the ability of our  muscular system to perform 
movements is regulated. Neuronal dopamine receptor  deficiency causes motor 
disability problems, such as those observed in  conditions like MSA-P and Parkinson's 
disease.  
RG-40 PROVIDES THE ORGANIC AMINO ACID PRECURSORS  REQUIRED FOR THE SYNTHESIS 
OF NEURONAL DOPAMINE RECEPTOR MOLECULES. 
Most drugs available today to treat Parkinson's  disease attempt to increase 
the concentration of the neurotransmitter dopamine  or its agonists in areas 
of the brain which are affected in Parkinson's disease.  However, the activity 
of these drugs is limited by the number of neuronal  dopamine receptors 
available to interact with the neurotransmitter dopamine or  its drug agonists. 
No matter how much a patient increases the  dosage of dopamine precursors 
like Sinemet, or of any of the dopamine agonists  drugs, if there are not enough 
neuronal dopamine receptors to interact with,  these drugs will not produce 
any further response at all. 
This figure is a schematic diagram of a dopamine  receptor showing that it is 
a protein arranged essentially as a long chain of  amino acids. 
The chain of amino acids, forming the dopamine  receptor, winds in and out of 
the cell several times. This creates three regions  of the receptor. Firstly, 
the extracellular portions are those parts of the  chain entirely outside the 
neuron; secondly, the intracellular portions are  those segments of the chain 
entirely inside the neuron and thirdly, the  transmembrane portions, which 
are the regions of the receptor which reside  within the membrane of the neuron. 
Each and all of the amino acid and biological  factors required for the 
synthesis of this and other dopamine receptor  molecules, are present in the 
organic vegetable extract RG-40, which is now used  by all the PD and MSA patients 
participating in our studies. 
MSA-C. Olivopontocerebellar atrophy 
When MSA begins with imbalance, incoordination,  and difficulty in speaking 
(dysarthria), it is called olivopontocerebellar  atrophy; as the name suggests, 
this form of MSA is marked by degeneration in the  cerebellum, a structure 
involved in balance and learned motor tasks.  
The following patient suffers from this  type of MSA, which is also called 
also MSA-C because the areas affected involve  the cerebellum. 
Patients suffering from MSA-C usually do not  show any response to the 
standard parkinsonian medication. This is precisely the  case of the fourth patient 
presented in this video. She did not show any  response to Sinemet. Moreover, 
she was affected by serious side effects which  are not usually present, in 
the first year, in most of the patients using this  drug.  
We would like to suggest that this patient, as  many diagnosed today with 
MSA, might suffer from a high sensitivity to specific  synthetic chemicals. This 
chemical sensitivity might be a confusing determinant  when trying to diagnose 
the disease. 
This patient showed rapid improvement, after  using a purely organic dietary 
intervention. We can assume, therefore, that she  suffers from a high 
sensitivity to non-organic chemicals.  
This suggestion is endorsed by another  experience. When this patient started 
on a clinical trial for a new drug for  MSA, she had to drop out at the very 
beginning of the study, because of adverse  reactions and innumerable side 
effects. Most of the other patients in the trial  were not troubled by these side 
effects. The chemical sensitivity in this  patient is higher than normal.  
For this particular type of patient, who cannot  tolerate large doses of 
drugs, we need to consider prescribing organic  interventions with natural 
products that can help them in a similar way as with  the drugs, but without adverse 
reactions, that can sometimes confuse the  diagnosis. 
The following Parkinson's disease  patients, started on our neurogenic 
programme during 1998. A few months later,  he decided to explore other alternatives 
to treat their  disease. 
He was offered a treatment called:  DEEP BRAIN STIMULATION 
A few months later a deep brain stimulator was  implanted in the ventralis 
intermedius nucleus of the thalamus. 
The goal of Deep Brain Stimulation is to reduce  the activity of overactive 
brain structures. High-Frequency Electrostimulation  inhibits neuronal firing 
either by depolarisation or by facilitating the action  of inhibitory 
interneurons. 
The effects of Deep Brain Stimulation are  limited to tremor control and drug 
related dyskinesia. Patients with progressive  Parkinson’s disease may 
eventually become disabled by akinesia and impairment of  postural reflexes, 
requiring more aggressive pharmacotherapy.  
To find out the long term response to Deep Brain  Stimulation on this 
patient, we contacted him again in July 2002. He told us  that initially, he had a 
good response to Deep Brain Stimulation that lasted for  over a year.  
Gradually, he had to go on increasing the  dosages of Sinemet to 8, 10 and 12 
times a day.  
He requested to us, that he would like to go  back to using our extracts, to 
allow a reduction in Sinemet, because it was  causing him adverse reactions.  
We sent him our extract RG-42 and he made a  home-video for us, showing how 
he responded to our extract now, 4 years after a  deep brain stimulator had 
been implanted. 
We concluded from this experience, as well as  from various other similar 
cases, that patients undergoing Deep Brain  Stimulation will not be able to 
induce neurogenesis or neuronal reactivation in  a significant way. 
Our dietary intervention programme and extracts  can only help patients using 
a Deep Brian Stimulator in a palliative manner,  mainly to reduce adverse 
reactions, appearing after larger dosages of drugs have  to be gradually 
reinstated.

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn